ArticleJournal for immunotherapy of cancer2025

Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation.

Wenting Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.